ALYQ is a phosphodiesterase 5 inhibitor indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise ability. PAH is high blood pressure in the blood vessels of the lungs.
With over 550 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the US.
Currently, one in seven generic prescriptions dispensed in the US is filled with a Teva generic product.
Adcirca had annual total sales of approximately USD 490m in the US, according to IQVIA data as of November 2018.
ALYQ is indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II III symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases.
Teva Pharmaceutical Industries is in generic medicines, with innovative treatments in select areas, including CNS, pain and respiratory.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib